Results 81 to 90 of about 2,000 (177)

Pharmaceutical Sovereignty as HIV Justice: Colombia's Dolutegravir License and the Future of ART Access in Latin America

Journal of the International AIDS Society, Volume 29, Issue S3, July 2026.
Laura M. Cifuentes, Julien B. Brisson, Aarón Zea, Pierre‐Marie David   +3 more
wiley   +1 more source

Revolutionizing HIV treatment: unveiling the new frontiers of HIV capsid research

Acta Materia Medica
The HIV-1 capsid protein (CA) plays a crucial role in viral replication by orchestrating nuclear entry through interactions with host nuclear pore complexes (NPCs).
Mei Wang, Shujing Xu, Haiyong Jia, Peng Zhan   +3 more
doaj   +1 more source

Structure of HIV-1 and HIV-2 CA and binding mode of lenacapavir.

(A) Structural alignment of HIV-1 and HIV-2 CA. HIV-1 CA is represented based on a crystal structure (PDB ID: 6VKV) [69], while the structure of HIV-2 CA was modeled previously using AlphaFold [82].
Gyula Hoffka (20904100), József Tőzsér (665273), Mohamed Mahdi (665270), János András Mótyán (3804706), Botond Lakatos (12478740)   +4 more
core   +1 more source

Antiretroviral drugs from multiple classes induce loss of excitatory synapses between hippocampal neurons in culture

Frontiers in Pharmacology
Introduction: Antiretroviral (ARV) drugs have improved prognoses for people living with HIV. However, HIV-associated neurocognitive disorders (HAND) persist despite undetectable viral loads. Some ARVs have been linked to neuropsychiatric effects that may
Hannah M. McMullan, Benjamin M. Gansemer, Stanley A. Thayer   +2 more
doaj   +1 more source

Lenacapavir Plus Cabotegravir as Combination Treatment: Real-world Use Cases From the National Clinician Consultation Center

Open Forum Infectious Diseases
Background The use of long-acting injectable (LAI) lenacapavir (LEN) plus cabotegravir (CAB) +/− rilpivirine (RPV) may increase viral suppression in people with HIV (PWH) with a history of oral antiretroviral therapy (ART) adherence challenges or drug ...
P. Saberi, Cara McAnaney, April Nakayoshi, Christopher M Bositis, Monica Gandhi, Carolyn Chu   +5 more
semanticscholar   +1 more source

Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry

Lenacapavir, the first-in-class capsid inhibitor, targets multiple stages of the HIV lifecycle, thereby inhibiting viral replication.1 Thanks to its new mechanism of action, lenacapavir is approved for use in people with HIV (PWH) who have limited ...
Lagi, Filippo, Santoro, Maria Mercedes, Capra N., Galli A., Trizzino M., Nardi S., Magnani S., Paggi A. M., Pontiggia S., Viale P., Celesia M., Bevilacqua L., Gulminetti R., Di Perri G., Bartoloni, Alessandro, Santoro M. M., Castelli F., Mongiardi S., Bartoloni A., Trevisan, Sasha, Feasi M., Colafigli M., Pincino R., Bassani F., Calleri G., Menzaghi B., Carli F., Spagnuolo, Vincenzo, Caputo S. L., Ferrari A., Antinori S., Cascio A., Mulas T., Torti C., Bellucci A., Minisci D., Piromalli G., Capra, Nicolò, D'Amico F., Fronti E., Giarratana C., Santantonio T., Cattelan A. M., Bottanelli M., Riccardi R., Gallicchio A., Compagno M., Moioli C., Saracino A., Tumbarello M., Calza L., Costa C., Castagna A., Cervo A., Sasha T., Di Giambenedetto S., Demitri M., Elena S., Madeddu G., Sara A., Fiscon M., De Socio G. V., Mussini C., Pagnucco L., Lolatto R., Valenti D., Laccabue D., Cacopardo B., Gasparro, Giuseppe, Fusco P., Comi L., Saladini F., Orofino, Giancarlo, Schioppa O., Brambilla P., Gagliardini R., Lagi F., Paterno Raddusa M. S., Schiaroli E., Corsi P., Bonora S., Giacomelli A., Marchetti G., Malerba F., Cretella S., Bagaglio S., Salvo P., Pan A., Clemente T., Da Ros V., Giuseppe G., De Vito A., Zazzi M., Lolatto, Riccardo, Tavio M., Malagnino V., Ferrara M., Mazzitelli M., Formenti T., Manzillo E., Rancan I., Torkjazi, Golnaz, Lamonica S., Calcagno A., Bassoli C. R., Balena F., Sarmati L., Orofino G., Olivadese V., Spagnuolo V., Fiscon, Marta, Foca E., Farinazzo M., Abeli C., Rusconi S., Fornabaio C., Gazzola L., Fabbiani M., Giada V., Muccini C., Trionfo Fineo F., Gagliardini, Roberta, Rossetto S., Laurenda D., Armenia D., Marta G., Carini E., Garlassi E., Torkjazi G., Bassetti M., Panza F., Fantino S., De Socio, Giuseppe Vittorio, Cenderello G., Francisci D., Cattelan, Anna Maria, Serena S., Nardini G., Corsini R., Narducci A., Blanchi S., Mariabelli E., Pontali E., Papaioannu Borjesson R., Fronti, Elisa, Ferrara S., Puoti M., Clemente, Tommaso, Piconi S., Di Biagio A., Zanussi S., Fusto M.   +151 more
core   +1 more source

Efficacy and Safety of Lenacapavir for HIV Treatment and Prevention: A Systematic Review

Lenacapavir, a first-in-class capsid inhibitor, represents a significant innovation due to its unique mechanism of action, targeting multiple stages of the viral replication cycle.
Takunda Mukuhlani
core   +1 more source

Beyond Efficacy: The Access, Delivery Systems, Acceptability, Persistence, and Transition Management “ADAPT” Framework for Long-Acting Injectable PrEP in Sub-Saharan Africa

HIV/AIDS: Research and Palliative Care
Eric Nzirakaindi Ikoona,1 Lucy Namulemo,2 Ronald Kaluya,3 Rebecca Ikoona,4 Foday Sahr51Department of Evaluation and Research, National Public Health Agency, Freetown, Sierra Leone; 2Department of Treatment Services, Foothills Community-Based ...
Ikoona EN, Namulemo L, Kaluya R, Ikoona R, Sahr F   +4 more
doaj  

Health impact, budget impact, and price threshold for cost-effectiveness of lenacapavir for HIV pre-exposure prophylaxis in eastern and southern Africa: a modelling analysis

The Lancet HIV
Summary Background Injectable lenacapavir administered every 6 months is a promising product for HIV pre-exposure prophylaxis (PrEP). We aimed to estimate the health and budget impacts and threshold price at which lenacapavir could be cost-effective in ...
Lin-Xuan Wu, D. Kaftan, R. Wittenauer, C. Arrouzet, N. Patel, Arden L Saravis, Brian Pfau, E. Mudimu, A. Bershteyn, Monisha Sharma   +9 more
semanticscholar   +1 more source

Biocatalytic Production of a Key Chiral Intermediate of the HIV Capsid Inhibitor Lenacapavir

Lenacapavir is a first-in-class viral capsid inhibitor approved for the treatment of HIV, which has been shown to give almost complete protection against transmission of the virus.
Finnigan, William, Hutton, Amy E., Green, Anthony, Crawshaw, Rebecca, Birmingham, William, Xu, Zefei, Zhao, Fei, Levy, Colin; id_orcid, Rowles, Ian, Turner, Nicholas; id_orcid, Taylor, Christopher, Dunstan, Mark; id_orcid, Ford, Grayson, Ortmayer, Mary   +13 more
core   +1 more source